EAM
ARIA

Eagle Asset Management’s Ariad Pharmaceuticals Inc ARIA Stock Holding History

Eagle Asset Management’s Portfolio ARIA Stock Details ARIA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-4,536,999
Closed -$84.8M – 677
2013
Q3 		$84.8M Sell
4,536,999
-401,044
-8% -$7.79M 0.42% 68
2013
Q2 		$86.4M Buy
+4,938,043
New +$87.5M 0.57% 32

Other funds holding ARIA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $178M AUM 118.43% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Eagle Asset Management's ARIA Position: Q4 2013 in Review

Eagle Asset Management sold out of Ariad Pharmaceuticals Inc (ARIA) in Q4 2013, closing a stake of 4,536,999 shares — an estimated $84.8M sold.

Eagle Asset Management first reported a position in ARIA in Q2 2013 and held it in 2 quarters. The position peaked at $86.4M in Q2 2013. 166 funds tracked by Wall St. Rank hold ARIA as of Q4 2013.

  • Eagle Asset Management reported no remaining Ariad Pharmaceuticals Inc position as of Q4 2013 after selling out during the quarter.
  • Eagle Asset Management sold 4,536,999 Ariad Pharmaceuticals Inc shares in Q4 2013, an estimated $84.8M.
  • Eagle Asset Management first reported a position in Ariad Pharmaceuticals Inc in Q2 2013 and held it in 2 quarters.
  • Eagle Asset Management's Ariad Pharmaceuticals Inc position peaked at $86.4M in Q2 2013.
  • 166 funds tracked by Wall St. Rank held Ariad Pharmaceuticals Inc as of Q4 2013.

Based on Eagle Asset Management's 13F filing for Q4 2013, filed 29 Jan 2014.